T1	Qualifier 18 41	cytologically confirmed
T2	Qualifier 0 14;32 41	Histologically confirmed
T3	Condition 42 70	adenocarcinoma of the breast
T4	Condition 96 114	metastatic disease
T5	Condition 107 114;76 92	disease locally advanced
T6	Condition 122 148	candidate for chemotherapy
T7	Procedure 136 148	chemotherapy
R1	multi Arg1:T6 Arg2:T7	
R2	AND Arg1:T3 Arg2:T5	
R3	AND Arg1:T3 Arg2:T4	
*	OR T1 T2
T8	Scope 0 41	Histologically or cytologically confirmed
T9	Scope 42 114	adenocarcinoma of the breast with locally advanced or metastatic disease
R4	Has_scope Arg1:T9 Arg2:T8	
R5	AND Arg1:T9 Arg2:T6	
T10	Measurement 151 198	Human epidermal growth factor receptor 2 (HER2)
T11	Value 199 207	positive
R6	Has_value Arg1:T10 Arg2:T11	
T12	Procedure 219 231	chemotherapy
T13	Temporal 213 218	prior
T14	Negation 210 212	No
R7	Has_temporal Arg1:T12 Arg2:T13	
R8	Has_negation Arg1:T12 Arg2:T14	
T15	Person 296 299	Age
T16	Value 300 310	â‰¥ 18 years
R9	Has_value Arg1:T15 Arg2:T16	
T17	Condition 275 293	Measurable disease
T18	Condition 242 272	metastatic breast cancer (MBC)
R10	AND Arg1:T12 Arg2:T18	
T19	Person 317 322	women
T20	Condition 326 348	childbearing potential
T21	Person 353 356	men
T22	Observation 357 396	with partners of childbearing potential
T23	Scope 317 348	women of childbearing potential
T24	Scope 353 396	men with partners of childbearing potential
T25	Scope 317 396	women of childbearing potential and men with partners of childbearing potential
A1	Optional T25
*	OR T23 T24
T26	Qualifier 417 433	highly effective
T27	Qualifier 435 447	non-hormonal
T28	Procedure 456 469	contraception
R11	Has_qualifier Arg1:T28 Arg2:T27	
R12	Has_qualifier Arg1:T28 Arg2:T26	
T29	Multiplier 473 474	2
T30	Procedure 494 520	non-hormonal contraception
R13	Has_multiplier Arg1:T30 Arg2:T29	
*	OR T28 T30
T31	Procedure 552 565	Contraception
T32	Temporal 575 619	continue for the duration of study treatment
T33	Reference_point 604 619	study treatment
R14	Has_index Arg1:T32 Arg2:T33	
T34	Temporal 624 684	for at least 6 months after the last dose of study treatment
T35	Reference_point 652 684	the last dose of study treatment
R15	Has_index Arg1:T34 Arg2:T35	
R16	Has_temporal Arg1:T31 Arg2:T32	
R17	Has_temporal Arg1:T31 Arg2:T34	
T36	Person 686 690	Male
T37	Observation 706 727	partners are pregnant
T38	Device 739 746	condoms
T39	Temporal 747 776	for the duration of the study
R18	Has_temporal Arg1:T38 Arg2:T39	
T40	Scope 686 727	Male patients whose partners are pregnant
A2	Optional T40
R19	AND Arg1:T40 Arg2:T38	
